Powerful Partnering for Positive Outcomes

With decades of experience conducting clinical trials in multiple therapeutic areas, Emeritus Research proudly provides the best outcomes for participants and sponsors. Our network of sites in Sydney and Melbourne conduct Phase I to Phase IV trials in our purpose built out-patient facilities. Working closely with your team and understanding your objectives allows us to implement a tailored approach to meeting your clinical trial requirements.

What makes us unique?




Equipped for Success

Equipped for Success

Highly trained staff and high-end equipment allow for the seamless and first-rate implementation of your protocols. Our combined sites give a unique opportunity to conduct your trials in multiple states using one reliable and successful company. Check out our outstanding capabilities below.

Maximising Participants

We deliver on rapid high volume enrolment targets with expert recruitment

Clinibase Partnership

Clinibase Partnership

Our industry leading recruitment providers Clinibase are experts on maximising recruitment. Utilising a digital marketing team they recruit using advertising methods to generate interest for clinical trials, then using thorough pre-screening techniques will identify potentially suitable participants for all trials. See all our recruitment achievements we have made in collaboration with Clinibase here.

Adding Expertise and Value to Your Project

  • Emeritus Research has centrally managed business development, start up, finance and quality to provide consistent outcomes.
  • Our dedicated Quality Team are continuously reviewing our processes, identifying areas of concern, and providing training to our team for continuous improvement.
  • Each team member performs standard procedural, policy, and clinical trial training through Qualio, our Learning Management System.

National Clinical Trial Sites

Our clinical trial sites conveniently located in Melbourne and Sydney

Get in touch to discuss your next project


Subscribe to the Emeritus Research newsletter for the latest news and events.